13 julio 2015
Children with inflammatory bowel disease who are doing well on specific biological medications should not be switched to recently approved ‘biosimilar’ products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.img src=»http://feeds.feedburner.com/~r/sciencedaily/~4/zOrvEC2reHE» height=»1″ width=»1″ alt=»»/
http://feeds.sciencedaily.com/~r/sciencedaily/~3/zOrvEC2reHE/150713122035.htm
